TheraPEG technology is used for the site-specific attachment of polyethylene glycol (PEG) polymer to therapeutic proteins.
TheraPEG offers site-specific conjugation to disulfide bonds to achieve better product homogeneity and efficient PEGylation process for improved production economics.
NU100 is poised to enter Phase 3 clinical studies in 2011 based on recent positive regulatory advice from the European Medicines Agency (EMEA).
Nuron Biotech CEO and founder Shankar Musunuri said this new program, NU400 further enhances the product profile of their lead program for Relapse Remitting Multiple Sclerosis (RRMS) and supports long-term life cycle strategy in the MS area.